Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?

Roch Houot, Ronald Levy, Guillaume Cartron, Philippe Armand, Roch Houot, Ronald Levy, Guillaume Cartron, Philippe Armand

Abstract

A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic.

Keywords: Anti-CD20 antibody; COVID-19; Rituximab; SARS-CoV-2; Vaccine.

Conflict of interest statement

Conflict of interest statement R.H. reports receiving honoraria from Bristol-Myers Squibb, MSD, Gilead, Kite, Roche, Novartis, Janssen, and Celgene. R.L. reports receiving honoraria from Apexigen, Beigene, Forty-Seven, Teneobio, Sutro, Checkmate, Nurix, Dragonfly, Quadriga, GigaGen, Abpro, Spolight, Xcella, Immunoscore, and Walking Fish. G.C. reports receiving honoraria from Roche, Celgene, Abbvie, Sanofi, Gilead, and Janssen. P.A. reports receiving honoraria from Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome; has received research funding from Genentech, Merck, BMS, Affimed, Adaptive, Roche, Tensha, and IGM.

Copyright © 2020 Elsevier Ltd. All rights reserved.

References

    1. Chandrashekar A., Liu J., Martinot A.J., McMahan K., Mercado N.B., Peter L. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 doi: 10.1126/SCIENCE.ABC4776. (80-)
    1. Yu J., Tostanoski L.H., Peter L., Mercado N.B., McMahan K., Mahrokhian S.H. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 doi: 10.1126/SCIENCE.ABC6284. (80-)
    1. Du L., Tai W., Zhou Y., Jiang S. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016;15:1123–1134. doi: 10.1586/14760584.2016.1167603.
    1. Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020 doi: 10.1007/s40121-020-00300-x.
    1. Corey B.L., Mascola J.R., Fauci A.S., Collins F.S. A strategic approach to COVID-19 vaccine R&D. Science. 2020:5312. doi: 10.1126/science.abc5312.
    1. Li L., Zhang W., Hu Y., Tong X., Zheng S., Yang J. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. J Am Med Assoc. 2020 doi: 10.1001/jama.2020.10044.
    1. Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. J Am Med Assoc. 2020;323:1582. doi: 10.1001/jama.2020.4783.
    1. Williamson E., Walker A.J., Bhaskaran K.J., Bacon S., Bates C., Morton C.E. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. MedRxiv. 2020 doi: 10.1101/2020.05.06.20092999. 2020.05.06.20092999.
    1. Mehta V., Goel S., Kabarriti R., Cole D., Goldfinger M., Acuna-Villaorduna A. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Canc Discov. 2020 doi: 10.1158/-20-0516.
    1. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. . 10.1200/JCO.1998.16.8.2825.
    1. Yri O.E., Torfoss D., Hungnes O., Tierens A., Waalen K., Nordøy T. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118:6769–6771. doi: 10.1182/blood-2011-08-372649.
    1. Bedognetti D., Zoppoli G., Massucco C., Zanardi E., Zupo S., Bruzzone A. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011;186:6044–6055. doi: 10.4049/jimmunol.1004095.
    1. Takata T., Suzumiya J., Ishikawa T., Takamatsu Y., Ikematsu H., Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop. 2009;49:9–13. doi: 10.3960/jslrt.49.9.
    1. Van Der Kolk L.E., Baars J.W., Prins M.H., Van Oers M.H.J. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100:2257–2259. doi: 10.1182/blood.v100.6.2257.h81802002257_2257_2259.
    1. Bingham C.O., Looney R.J., Deodhar A., Halsey N., Greenwald M., Codding C. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64–74. doi: 10.1002/art.25034.
    1. Kim W., Kim S.H., Huh S.Y., Kong S.Y., Choi Y.J., Cheong H.J. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol. 2013;20:975–980. doi: 10.1111/ene.12132.
    1. Eisenberg R.A., Jawad A.F., Boyer J., Maurer K., McDonald K., Prak E.L. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013;33:388. doi: 10.1007/S10875-012-9813-X.
    1. Nazi I., Kelton J.G., Larché M., Snider D.P., Heddle N.M., Crowther M.A. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122:1946–1953. doi: 10.1182/blood-2013-04-494096.
    1. Omarini C., Maur M., Luppi G., Narni F., Luppi M., Dominici M. Cancer treatment during the coronavirus disease 2019 pandemic: do not postpone, do it! Eur J Canc. 2020;133:29–32. doi: 10.1016/j.ejca.2020.04.034.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj